ASCO 2017: Phase II study of alternate sunitinib schedule in patients with metastatic renal cell carcinoma

Chicago, IL ( Dr. Jonasch and colleagues presented their results of a phase II study alternating sunitinib schedule for patients with metastatic renal cell carcinoma (mRCC) at today’s 2017 ASCO annual meeting genitourinary cancer poster session. Considering that sunitinib typically given in a 4 week on, 2 week off schedule (4/2) results in significant toxicity in the third and fourth week of therapy, the authors hypothesized that a 2 week on, 1 week off schedule (2/1) would result in improved toxicity profile without compromising oncologic efficacy.

In order to complete this trial, the authors utilized a multicenter, single arm approach. Patients were initiated on a sunitinib 50mg 2/1 schedule and dose alterations were performed if grade >3 toxicities were experienced. The primary outcome was percentage of patients who experienced grade >3 fatigue, diarrhea, or hand-foot syndrome (HFS). Secondary outcomes were (i) response rate, (ii) progression free survival (PFS), and (iii) dose reduction. Over a two-year period, 60 patients were enrolled in this phase II trial and 59 patients were treated. The median age was 65.5 years (range 45-92) and 24% of patients had grade >3 toxicity (95%CI: 13.6%-36.6%). The authors note that this is similar to the average toxicity profile of the 4/2 schedule of 25%-30%. Thirty-seven percent of patients responded to therapy, and among patients with secondary endpoint data available, median PFS was 19.3 months (95%CI 8.2-NR) and 59% of patients underwent dose reduction. A possible limitation of this trial is lack of a 4/2 dose schedule control arm.

The authors concluded that sunitinib administered in a 2/1 dose schedule did not result in a lower rate of grade 3 or higher fatigue, diarrhea or HFS when compared to historical data from trials employing a 4/2 schedule. Encouragingly, oncologic efficacy data showed a robust response rate and prolonged PFS, suggesting that patients tolerating sunitinib on a 2/1 schedule may not be at risk of inferior outcomes. Further toxicity kinetics and evaluation of patient quality of life metrics are ongoing.
Clinical trial: NCT02060370

Presented By: Eric Jonasch, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Co-Authors: Rebecca Slack, Daniel M. Geynisman, Matthew I. Milowsky, Kimryn Rathmell, Summer Stovall, Donna Juarez, Elizabeth R. Plimack, Nizar M. Tannir, Brian I. Rini

Written By: Zachary Klaassen, MD, Urologic Oncology Fellow, University of Toronto, Princess Margaret Cancer Centre
Twitter: @zklaassen_md

at the 2017 ASCO Annual Meeting - June 2 - 6, 2017 – Chicago, Illinois, USA

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.